WHO Updates Essential Medicines List for Hemophilia and VWD: Louise Bannon Applauds Global Hematology Community’s Achievement
Louise Bannon, Director of Membership, Marketing and External Relations of ISTH, shared a post on LinkedIn:
”In today’s news!
WHO Updates Essential Medicines List to Improve Care for People with Bleeding Disorders
The World Health Organization (WHO) has updated its Essential Medicines List (EML) and Essential Medicines List for Children (EMLc) to better align with international clinical guidelines for the management of hemophilia and von Willebrand Disease (VWD).
These revisions will help ensure that decision makers worldwide are guided by the latest evidence when selecting and financing essential medicines, improving access to safer and more effective therapies for people with bleeding disorders (PWBDs).
Key updates include:
- New medicines added: Bi-specific monoclonal antibody emicizumab; recombinant FVIII and FIX clotting factor concentrates (CFCs)
- Existing medicines upgraded: Plasma-derived FVIII and FIX CFCs and desmopressin moved from the complementary to the core list
- Medicines removed: Pathogen-reduced and non-pathogen-reduced cryoprecipitate and Factor IX Complex (PCC)
Congratulations to the global hematology community for advocating strongly to achieve these revisions, ensuring that people with bleeding disorders have access to modern, safe, and effective therapies.
ISTH applauds the leadership of the World Federation of Hemophilia (WFH) and its partners for mobilizing this milestone effort and supporting equitable treatment access worldwide.”
Find the latest news in the World of Bleeding Disorders featured in Hemostasis Today.
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH
-
Sep 9, 2026, 16:07Zahra Safarzadeh: From Novel F8 Variant to Clinical Significance
-
Sep 9, 2026, 16:00Maximo Agustin Schiavone: HDL Beyond Cholesterol – Linking Lipids and Immunity
-
Sep 9, 2026, 15:56Abdul Mannan: When Antiseizure Drugs Alter DOAC Risk